Celgene in talks to buy Juno Therapeutics - WSJ

Shares of Juno, which has a market value of $5.57 billion,were up 42 percent at $64.59 in extended trading.Chimeric antigen receptor T-cell therapy, or CAR T, harnesses the body's own immune cells to recognize and attack malignant cells.